23 December 2013

Appointment of CEO and Chairman

Merrion Pharmaceuticals plc (ESM: MERR), announced today that John Fox has been appointed as Chief Executive Officer and as a director of Merrion with effect from January 1, 2014.  In addition, the board has appointed Michael McKenna as non executive Chairman in place of Michael Donnelly who is stepping down from his current role as Executive Chairman.

Merrion Lead Independent Director Harry Stratford commented: On behalf of the Merrion board, I would like to thank Michael Donnelly for his contribution as Chairman since December 2011 and I look forward to continuing to work with Michael as a non-executive director of the Company.  I would also like to welcome John Fox (who was previously Merrion's Chief Development Officer) to his new role as CEO and I look forward to continuing to work with our incoming chairman, Michael McKenna.  These new appointments will both strengthen Merrion's operational capabilities and further enhance our links with the important United States market.

 Investor Enquiries:

Investor Enquiries:
Merrion Pharmaceuticals Plc.
John Fox
T +353 1 642 3300
www.merrionpharma.com		 Media Enquiries:
Slattery Communications
Conor Dempsey
T +353 (0)86 247 9892
E-mail: conor.dempsey@scomms.ie
Davy Corporate Finance
Ivan Murphy
T +353 1 679 6363
distributed by